Indication: Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Sub-indication: Neuroblastoma
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Children's Oncology Group (COG)
Learn more at ClinicalTrials.gov
Email for more information: NCRI-Cancer@NortonHealthcare.org